Vena cava filter use in cancer patients with acute venous thromboembolism in California

Thrombosis Research
Gwendolyn HoTed Wun

Abstract

Few studies have evaluated the use of vena cava filters (VCF) in cancer patients with acute venous thromboembolism (VTE). Hospital discharge records of patients who were admitted with a principal diagnosis of lower extremity deep-vein thrombosis or pulmonary embolism and cancer in California between January 1, 2005 and December 31, 2009 were analyzed. Multivariable logistic regression analysis was used to identify variables associated with VCF use. A VCF was placed in 2747 (19.6%) of 14,000 cancer patients. The percentage of patients treated with a VCF varied widely across hospitals, from 0% to 52% (mean=19.2%, median=17.2%), and by cancer type, ranging from 8% for lip/oral to 43% for brain. Using multivariable analysis, the strongest predictors of VCF use were a diagnosis of brain cancer (OR=4.6, CI: 3.7 -5.6), undergoing major surgery (OR=4.9, CI: 3.9 -6.1), and bleeding (OR=2.7, CI: 2.0-3.5). Other factors significantly associated with VCF insertion included hospital characteristics (larger, urban and private), and greater severity-of-illness at the time of admission. Only 1083 (7.7%) of patients had an absolute contraindication to anticoagulation (bleeding or surgery). A VCF was deployed in approximately 20% of acute VTE pa...Continue Reading

References

Sep 19, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Quan ChauLinda S Elting
Jul 28, 2004·Archives of Internal Medicine·Paul D SteinRonald E Olson
Sep 24, 2004·Cancer·Michael J WallaceMarshall E Hicks
Sep 8, 2005·The Journal of Urology·Joseph A Smith
Mar 1, 2006·Archives of Internal Medicine·Helen K ChewRichard H White
Sep 9, 2006·Vascular and Endovascular Surgery·Christian SchunnUsman Waheed
Sep 12, 2006·Journal of Thrombosis and Haemostasis : JTH·M MonrealUNKNOWN Riete Investigators
Aug 9, 2007·Medical Care Research and Review : MCRR·Julie A SchoenmanDenise Love
Apr 4, 2008·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Myra F BarginearDaniel R Budman
Apr 17, 2009·The Journal of Arthroplasty·Carlos J LaverniaMark D Rossi
Sep 2, 2009·Annals of Internal Medicine·Daniel E SingerAlan S Go
Sep 15, 2010·Archives of Internal Medicine·Frederick A SpencerRichard H White
Dec 3, 2010·Surgical Neurology International·Aaron Roberts, William F Young
May 20, 2011·The American Journal of Medicine·Paul D SteinRussell D Hull
Jul 5, 2011·Journal of the American College of Radiology : JACR·Richard DuszakVijay M Rao
Nov 14, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alex J WalkerMatthew J Grainge
Apr 5, 2013·JAMA Internal Medicine·Richard H WhitePatrick S Romano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Related Papers

Hematology/oncology and Stem Cell Therapy
Asem MansourHikmat Abdel-Razeq
Therapeutics and Clinical Risk Management
Hikmat Abdel-RazeqHazem Abdulelah
Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine
Marianne TschoeMichael B Streiff
© 2022 Meta ULC. All rights reserved